EUVIMEDEUVIMED entdecken
Crossref

Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV

Luis Ramos-Ruperto iD, Maria Del Mar Arcos-Rueda iD, Rosa de Miguel-Buckley, Carmen Busca-Arenzana, Rafael Mican, Rocío Montejano, Ana Delgado-Hierro, María Luisa Montes iD, María Eulalia Valencia, Lucía Serrano, José Ramon Arribas, Juan González und 2 weitere

HIV Medicine · 2024

DOI: 10.1111/hiv.13617 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2024. Verfasst von Luis Ramos-Ruperto und 13 weiteren Autor:innen. Beteiligte Einrichtung: HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain. Hauptthemen laut MEDLINE: Rilpivirine, Pyridones, Heterocyclic Compounds, 3-Ring, Oxazines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dolutegravir + rilpivirine (DTG + RPV) is an effective antiretroviral therapy regimen approved in clinical guidelines as a switch therapy for virologically suppressed people with HIV. Our study aimed to compare the effectiveness and tolerability of DTG + RPV in women and men in real‐world clinical practice.

Methods

This was a retrospective analysis of treatment‐experienced people with HIV from a large HIV unit who switched to DTG + RPV. We analysed treatment effectiveness, rates of adverse events and discontinuation, and metabolic changes after 48 weeks of treatment. HIV‐RNA levels

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirinePyridonesHeterocyclic Compounds, 3-RingOxazinesHIV InfectionsPiperazinesAnti-HIV AgentsHumansFemaleMaleRetrospective StudiesAdultMiddle AgedTreatment OutcomeSex FactorsDrug SubstitutionViral LoadRNA, ViralDolutegravir

Stichwörter der Autor:innen

DTG + RPVDolutegravirHIVRilpivirinegender

Substanzen

RilpivirinePyridonesHeterocyclic Compounds, 3-RingOxazinesPiperazinesAnti-HIV AgentsRNA, ViralDolutegravir

Autor:innen und Institutionen

  • HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain.
  • CIBER de Enfermedades Infecciosas CIBER INFECC, Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Luis Ramos-Ruperto, Maria Del Mar Arcos-Rueda, María Luisa Montes

Zitieren

APA

Ramos-Ruperto, L., Arcos-Rueda, M. D. M., de Miguel-Buckley, R., Busca-Arenzana, C., Mican, R., Montejano, R., Delgado-Hierro, A., Montes, M. L., Valencia, M. E., Serrano, L., Arribas, J. R., González, J., Bernardino, J. I., & Martín-Carbonero, L. (2024). Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV. HIV Medicine. https://doi.org/10.1111/hiv.13617

Vancouver

Ramos-Ruperto L, Arcos-Rueda MDM, de Miguel-Buckley R, Busca-Arenzana C, Mican R, Montejano R, et al. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV. HIV Medicine. 2024. doi:10.1111/hiv.13617

BibTeX
@article{RamosRuperto2024,
  author = {Ramos-Ruperto, Luis and Arcos-Rueda, Maria Del Mar and de Miguel-Buckley, Rosa and Busca-Arenzana, Carmen and Mican, Rafael and Montejano, Rocío and Delgado-Hierro, Ana and Montes, María Luisa and Valencia, María Eulalia and Serrano, Lucía and Arribas, José Ramon and González, Juan and Bernardino, Jose Ignacio and Martín-Carbonero, Luz},
  title = {Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV},
  journal = {HIV Medicine},
  year = {2024},
  doi = {10.1111/hiv.13617}
}
Kostenlos starten →